These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8174849)

  • 21. The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
    Nishimura C; Hotta Y; Gui T; Seko A; Fujimaki T; Ishikawa T; Hayakawa M; Kanai A; Saito T
    Diabetes Res Clin Pract; 1997 Sep; 37(3):173-7. PubMed ID: 9306038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
    Oishi N; Kubo E; Takamura Y; Maekawa K; Tanimoto T; Akagi Y
    Br J Ophthalmol; 2002 Dec; 86(12):1363-6. PubMed ID: 12446366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?
    Ito T; Nishimura C; Takahashi Y; Saito T; Omori Y
    Diabetes Res Clin Pract; 1997 Jun; 36(3):161-7. PubMed ID: 9237782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldose reductase and diabetic retinopathy.
    Singh R; Dash D; Ansari FJ; Maurya OP; Singh VP
    Ann Ophthalmol; 1992 Nov; 24(11):420-2. PubMed ID: 1476398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
    Takahashi Y; Tachikawa T; Ito T; Takayama S; Omori Y; Iwamoto Y
    Diabetes Res Clin Pract; 1998 Nov; 42(2):101-7. PubMed ID: 9886746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardization of hemoglobinometry. II. The hemiglobincyanide method.
    van KAMPEN E; ZIJLSTRA WG
    Clin Chim Acta; 1961 Jul; 6():538-44. PubMed ID: 14453500
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
    Hamada Y; Kitoh R; Raskin P
    Diabet Med; 1993; 10(1):33-8. PubMed ID: 8435985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reductase.
    Nishimura C; Furue M; Ito T; Omori Y; Tanimoto T
    Biochem Pharmacol; 1993 Jul; 46(1):21-8. PubMed ID: 8347133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG; Kador PF; Kinoshita JH
    Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental galactosemia produces diabetic-like retinopathy.
    Engerman RL; Kern TS
    Diabetes; 1984 Jan; 33(1):97-100. PubMed ID: 6360771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythrocyte glyceraldehyde-reductase levels in diabetics with retinopathy and cataract.
    Crabbe MJ; Peckar CO; Halder AB; Cheng H
    Lancet; 1980 Dec; 2(8207):1268-70. PubMed ID: 6108447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity.
    Greene DA; Lattimer SA
    Diabetes; 1984 Aug; 33(8):712-6. PubMed ID: 6086432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The involvement of aldose reductase in diabetic complications.
    Kinoshita JH; Nishimura C
    Diabetes Metab Rev; 1988 Jun; 4(4):323-37. PubMed ID: 3134179
    [No Abstract]   [Full Text] [Related]  

  • 34. Depletion of myo-inositol and amino acids in galactosemic neuropathy.
    Nishimura C; Lou MF; Kinoshita JH
    J Neurochem; 1987 Jul; 49(1):290-5. PubMed ID: 3035099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system.
    Nishimura C; Yamaoka T; Mizutani M; Yamashita K; Akera T; Tanimoto T
    Biochim Biophys Acta; 1991 Jun; 1078(2):171-8. PubMed ID: 1905957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
    Nishimura C; Saito T; Ito T; Omori Y; Tanimoto T
    Diabetologia; 1994 Mar; 37(3):328-30. PubMed ID: 8174849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 38. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.